Yuhan Corporation (KRX:000100)

Market Cap	5.74T -28.8%
Revenue (ttm)	2.22T +5.1%
Net Income	209.30B +217.8%
EPS	2,804.37 +214.3%
Shares Out	74.76M
PE Ratio	27.42
Forward PE	40.54
Dividend	500.00 (0.65%)
Ex-Dividend Date	Feb 26, 2026

Volume	211,712
Open	75,200
Previous Close	76,700
Day's Range	74,200 - 77,300
52-Week Range	71,700 - 136,400
Beta	0.39
Analysts	Buy
Price Target	134,100.00 (+74.38%)
Earnings Date	Aug 14, 2026

About Yuhan

Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperl...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1926
• Employees: 2,067
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000100

Financial Performance

In 2025, Yuhan's revenue was 2.19 trillion, an increase of 5.75% compared to the previous year's 2.07 trillion. Earnings were 191.09 billion, an increase of 170.33%.

Analyst Summary

According to 20 analysts, the average rating for 000100 stock is "Buy." The 12-month stock price target is ₩134,100, which is an increase of 74.38% from the latest price.

Price Target

₩134,100

(74.38% upside)

Analyst Consensus: Buy